Abstract: A recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained by alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.

Abstract: A method for the production of a biomolecular complex having at least two functional elements each attached to a target molecule or area through binding elements, wherein each functional element is attached to a specific binding element, the binding element being a nucleotide sequence and the target molecule or area comprising the corresponding target sequence, and the target molecules or areas being separated from each other by a first linker or spacer and an optional second linker, the linkers being nucleic acid polymers having a pre-determined physical property.

Abstract: An isolated cell having a nucleic acid construct encoding a recombinant Na+, K+-ATPase ?1-subunit protein resistant to cardiac glycosides, e.g., ouabain, is disclosed. Selected amino acid substitutions in the normal human Na+, K+-ATPase ?1-subunit confers resistance to cardiac glycosides. Cardiac glycoside resistant Na+, K+-ATPase ?1-subunits may be useful as selection markers in gene therapy and research applications.

Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Abstract: The present invention relates to a method of introducing organic molecules carrying genetic information into isolated target cells, which comprises the step of passing a supernatant comprising said organic molecules through a fluidized collection of said target cells during an essentially constant flow. The fluidisation is provided by directing a flow of the supernatant so as to essentially counteract the gravitational force of the target cells, or alternatively a force applied thereon. Thus, the present method enables an efficient introduction of genetic information into the target cells.

Abstract: The present invention relates to a novel method of genetic modification, wherein a nucleic acid of interest is transferred across a biological membrane, and/or directed to a specific location within or on a cell, by use of a synthetic transport entity. The transport entity according to the invention is new as such and produced by coupling a functional element (FE), such as a nuclear localization signal (NLS), an antennapedia peptide of a protein comprising both membrane translocation and nuclear transport properties, to a binding element (BE), such as a peptide nucleic acid (PNA), preferably separated by a linker molecule, which combination is then hybridized to a BE target sequence present on a carrier, which also includes the nucleic acid of interest. The present nucleic acid of interest may for example be a gene encoding a peptide, a protein or an RNA, or any other nucleic acid useful in genetic recombination events.